Trial reportFrontiers in endocrinology2022
Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis.
Trial report in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.Virchows Archiv : an international journal of pathology · 2024Pooled it
- Article
- A dynamic nomogram and risk stratification system for predicting cancer-specific survival in patients with locally advanced differentiated thyroid cancer: a population-based study.Gland surgery · 2025Article
- Development of a Nomogram-Based Online Calculator for Predicting Cancer-Specific Survival in Patients With Digestive Tract Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): An Analysis of the SEER Database.Cancer reports (Hoboken, N.J.) · 2025Article
- Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors.Frontiers in oncology · 2025Article
- Development and validation of survival nomograms for patients with differentiated thyroid cancer with distant metastases: a SEER Program-based study.Journal of endocrinological investigation · 2024Article
- Evaluation of AJCC staging system and proposal of a novel stage grouping system in retroperitoneal liposarcoma: the Fudan Zhongshan experience.Frontiers in oncology · 2024Article
- A prognostic nomogram for the cancer-specific survival rate of choroidal melanoma using the Surveillance, Epidemiology, and End Results database.Frontiers in medicine · 2024Article
- Dynamic estimates of survival of patients with poorly differentiated thyroid carcinoma: a population-based study.Frontiers in endocrinology · 2024Article
- Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation.Frontiers in endocrinology · 2024Article
- Predictive factors and clinicopathological characteristics of outcome in poorly differentiated thyroid carcinoma: a single-institution study.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to establish and validate an accurate prognostic model, based on demographic and clinical parameters, for predicting the cancer-specific survival (CSS) of patients with poorly differentiated thyroid carcinoma (PDTC). Materials and methods: Patients diagnosed with PDTC between 2004 to 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Randomly split the data into training and validation sets. Kaplan-Meier analysis with the log-rank test was performed to compare the survival distribution among cases. Univariate and multivariate Cox proportional hazards regression analyses were used to identify independent prognostic factors, which were subsequently utilized to construct a nomogram for predicting the 5- and 10-year cancer-specific survival of patients with PDTC. The discriminative ability and calibration of the nomogram model were assessed using the concordance index and calibration plots, respectively. In addition, we performed a decision curve analysis to assess the clinical value of the nomogram. Simultaneously, we compared the predictive performance of the nomogram model against that of the American Joint Committee on Cancer (AJCC) T-, N-, M-stage. Results: A total of 970 eligible patients were randomly assigned to either a training cohort ( Conclusions: The nomogram developed by us can accurately predict the CSS of PDTC patients. It can help clinicians determine appropriate treatment strategies for poorly differentiated thyroid carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.